AbbVie on Twitter
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
October 09, 2017
-
October 09, 2017
-
October 05, 2017
-
October 04, 2017
October 04, 2017After a series of catastrophic natural disasters, AbbVie Foundation provides support with more than $4 million in grants.-
September 28, 2017- Agreements Provide Non-Exclusive License to Amgen for HUMIRA-Related Intellectual Property in the U.S. Effective Jan. 31, 2023, And in Other Markets on Different Dates
-
September 27, 2017- MAVIRET is the first and only 8-week treatment for genotype 1 and 2 hepatitis C virus (HCV) infected patients without cirrhosis and who are new to DAA treatment* in Japan
-
September 26, 2017
September 19, 2017During the Employee Giving Campaign, we’re helping our people do what comes naturally: give back to the nonprofits they love.-
September 18, 2017-- Results of a multicenter, open-label, randomized Phase 3 study of VENCLEXTA™/VENCLYXTO™ (Venetoclax) Tablets in combination with Rituxan® met the primary endpoint of prolonged progression-free survival compared with bendamustine in combination with Rituxan in patients with relapsed/refractory CLL
-
September 13, 2017- In honor of the program's 25th anniversary, AbbVie is awarding three $25,000 scholarships, including a new award category - the Blogger's Choice Award
-
September 11, 2017- SELECT-BEYOND, the second study in the robust SELECT program, demonstrated positive results with both doses (15 mg and 30 mg once-daily) meeting the primary endpoints in a difficult-to-treat patient population, over half of whom had previously been treated with two or more biologics(1)
-
September 08, 2017
-
September 07, 2017- Study shows positive results for upadacitinib and no new safety signals detected[1]
-
September 06, 2017- In clinical studies, elagolix demonstrated superiority compared to placebo in reducing three types of endometriosis-associated pain - daily menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse
-
September 05, 2017
August 30, 2017In the wake of a catastrophic storm, AbbVie Foundation works with nonprofit partners to bring relief.-
August 03, 2017- MAVYRET is a new 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment
-
August 02, 2017- Approval for the treatment of cGVHD is the sixth U.S. disease indication for the medication and the first therapy specifically approved for adults with cGVHD after failure of one or more lines of systemic therapy
Our history
 |
Explore where we've been and how we continue to go beyond medicine to make a remarkable impact. Learn more
Societal impact
 |
Our commitment to science is a commitment to better our society. Read our 2023 ESG report
Ratings and recognition
 |
We've been honored to receive some of the most prestigious ratings and recognnitions in the industry. Learn more
Annual report
 |
See our latest 2023 Annual Report on Form 10-K. Learn more
